FrancophonIA/ELRC3.0 huggingface dataset:
English: The patients were followed up for an average of four and a half years.
Croatian: Bolesnici su u prosjeku praćeni tijekom razdoblja od četiri i pol godine.
English: The full EPAR for Kinzalmono can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR za lijek Kinzalmono nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Kinzalmono na snazi u Europskoj uniji od 16. prosinca 1998.
English: Kinzalmono must not be used in women who are more than three months pregnant.
Croatian: Kinzalmono ne smiju uzimati žene koje su trudne dulje od tri mjeseca.
English: What measures are being taken to ensure the safe and effective use of Kinzalmono?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kinzalmono?
English: Other information about Kinzalmono
Croatian: Ostale informacije o lijeku Kinzalmono
English: This is a summary of the European public assessment report (EPAR) for Kinzalmono.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Kinzalmono.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Kinzalmono.
English: For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.
Croatian: Za potrebe prevencije kardiovaskularnih problema, preporučena doza je 80 mg jedanput na dan.
English: Kinzalmono is a medicine that contains the active substance telmisartan.
Croatian: Kinzalmono je lijek koji sadrži djelatnu tvar telmisartan.
English: Why has Kinzalmono been approved?
Croatian: Zašto je Kinzalmono odobren?
English: Kinzalmono was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines.
Croatian: Kinzalmono je uspoređen s ramiprilom (još jednim lijekom za prevenciju kardiovaskularnih problema) te s kombinacijom obaju lijekova.
English: Various doses of Kinzalmono were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Croatian: Različite doze lijeka Kinzalmono uspoređene su s placebom (prividnim liječenjem) te s drugim lijekovima za liječenje hipertenzije (atenololom, lizinoprilom, enalaprilom i amlodipinom).
English: Hypotension may be more common in patients receiving Kinzalmono to prevent cardiovascular problems.
Croatian: Hipotenzija se može pojaviti češće u bolesnika koji primaju lijek Kinzalmono radi prevencije kardiovaskularnih problema.
English: What is the risk associated with Kinzalmono?
Croatian: Koji su rizici povezani s lijekom Kinzalmono?
English: However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown).
Croatian: No, sljedeće su nuspojave zabilježene kod 1 do 10 bolesnika na 1000: infekcija gornjeg dišnog sustava (prehlade), uključujući upalu grla i sinusa, infekcija mokraćnog sustava (infekcija organa koje prenose mokraću), uključujući infekciju mjehura, anemija (mali broj crvenih krvnih stanica), hiperkalijemija (visoke koncentracije kalija u krvi), depresija, nesanica (poteškoće sa spavanjem), sinkopa (nesvjestica), vertigo (vrtoglavica), bradikardija (usporena frekvencija srca), hipotenzija (niski krvni tlak), dispneja (otežano disanje),
English: In the treatment of essential hypertension, Kinzalmono was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Croatian: U liječenju esencijalne hipertenzije, Kinzalmono je bio djelotvorniji od placeba u snižavanju dijastoličkog krvnog tlaka i imao je slično djelovanje kao drugi antihipertenzivi.
English: For more information about treatment with Kinzalmono, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Kinzalmono pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kinzalmono, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Kinzalmono nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: The active substance in Kinzalmono, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Croatian: Telmisartan, djelatna tvar u lijeku Kinzalmono, „antagonist je receptora angiotenzina II”, što znači da u tijelu blokira djelovanje hormona naziva angiotenzin II.
English: What is Kinzalmono?
Croatian: Što je Kinzalmono?
English: A risk management plan has been developed to ensure that Kinzalmono is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Kinzalmono.
English: Kinzalmono is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Croatian: Kinzalmono se također koristi radi sprječavanja kardiovaskularnih problema (problema sa srcem i krvnim žilama), primjerice srčanih ili moždanih udara.
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Kinzalmono must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Croatian: U bolesnika s dijabetesom tipa 2 ili u bolesnika s umjerenim ili ozbiljnim oštećenjem bubrežne funkcije, Kinzalmono se također ne smije primjenjivati u kombinaciji s lijekovima koji sadrže aliskiren (također se primjenjuje u liječenju esencijalne hipertenzije).
English: For the prevention of cardiovascular problems, 80 mg Kinzalmono once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems.
Croatian: Za potrebe prevencije kardiovaskularnih problema, doza od 80 mg lijeka Kinzalmono jednom na dan ispitivana je u jednom glavnom ispitivanju kojim je obuhvaćeno gotovo 26 000 bolesnika u dobi od 55 godina ili starijih koji su bolovali od bolesti srca ili arterijske bolesti, pretrpjeli moždani udar ili koji su bolovali od dijabetesa i bili izloženi visokom riziku od kardiovaskularnih problema.
English: Kinzalmono must not be used in people who have severe liver problems or bile problems.
Croatian: Kinzalmono se ne smije koristiti u osoba koje imaju ozbiljne probleme s jetrom ili žuči.
English: In the prevention of cardiovascular problems, Kinzalmono had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Croatian: U prevenciji kardiovaskularnih problema, Kinzalmono je imao slično djelovanje kao ramipril, pri čemu je otprilike 17 % bolesnika preminulo, hospitalizirano zbog kardiovaskularnih problema ili pretrpjelo srčani ili moždani udar.
English: Side effects with Kinzalmono are not common.
Croatian: Nuspojave lijeka Kinzalmono nisu uobičajene.
English: The CHMP decided that Kinzalmono's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: CHMP je odlučio da koristi od lijeka Kinzalmono nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: For the treatment of essential hypertension, the usual recommended dose of Kinzalmono is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Croatian: Za potrebe liječenja esencijalne hipertenzije, uobičajena preporučena doza lijeka Kinzalmono iznosi 40 mg jednom na dan, no u nekih se bolesnika može zabilježiti pozitivan učinak već pri dozi od 20 mg jednom na dan.
English: The doctor should monitor the patient's blood pressure closely when starting Kinzalmono, and may decide to adjust the patient's blood pressure-lowering medication.
Croatian: Pri započinjanju terapije lijekom Kinzalmono liječnik treba pomno pratiti krvni tlak bolesnika i može donijeti odluku o prilagodbi terapije za snižavanje krvnoga tlaka bolesnika.
English: For the treatment of essential hypertension, Kinzalmono has been studied in 2,647 patients who took Kinzalmono either alone or in combination with hydrochlorothiazide.
Croatian: Za potrebe liječenja esencijalne hipertenzije, Kinzalmono je ispitivan na 2647 bolesnika koji su taj lijek uzimali kao monoterapiju ili u kombinaciji s hidroklorotiazidom.
English: What is Kinzalmono used for?
Croatian: Za što se Kinzalmono koristi?
English: For the full list of all side effects reported with Kinzalmono, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Kinzalmono potražite u uputi o lijeku.
English: What benefit has Kinzalmono shown during the studies?
Croatian: Koje su koristi lijeka Kinzalmono utvrđene u ispitivanjima?
English: Kinzalmono is used to treat essential hypertension (high blood pressure) in adults.
Croatian: Kinzalmono se primjenjuje u liječenju esencijalne hipertenzije (visokog krvnog tlaka) u odraslih. „Esencijalne” znači da visok krvni tlak nije izazvan nijednim očitim uzrokom.
English: How is Kinzalmono used?
Croatian: Kako se Kinzalmono koristi?
English: How has Kinzalmono been studied?
Croatian: Kako je Kinzalmono ispitivan?
English: How does Kinzalmono work?
Croatian: Kako djeluje Kinzalmono?
English: Immediate Packaging Pack size
Croatian: Broj (EU) odobrenja (Zaštićeno) ime Doza Farmaceutski oblik Put primjene Unutarnje pakovanje Veličina pakovanja
English: Annex I List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, marketing authorisation holder(s) in the member states
Croatian: Dodatak I Popis naziva, farmaceutskog(ih) oblika, jačine(a) lijek(ov)a, put(ev)a primjene, nositelj(a) odobrenja u državama članicama
English: TAMIK, capsule soft capsule
Croatian: TAMIK, capsule meka kapsula
English: tablets
Croatian: tablete
English: SEGLOR LYOC 5 mg, lyophilisat oral oral lyophilisate
Croatian: SEGLOR LYOC 5 mg, lyophilisat oral oralni liofilizat
English: SEGLOR 5 mg, gélule 5 mg hard capsule
Croatian: SEGLOR 5 mg, gélule 5 mg tvrda kapsula
English: IKARAN L.P. 5 mg, comprimé à libération prolongée prolonged-release tablet
Croatian: IKARAN L.P. 5 mg, comprimé à libération prolongée tableta s produljenim oslobađanjem
English: 2.5 mg tablet
Croatian: 2.5 mg tableta
English: DHE "ratiopharm" 2,5 mg - Kapseln prolonged-release capsule, hard ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Croatian: DHE "ratiopharm" 2,5 mg - Kapseln ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
English: DET MS Tropflösung 2 mg/ 1 ml
Croatian: DET MS Tropflösung 2 mg/ 1 ml otopina
English: Effortil comp. - Tropfen 2 mg/ml, 10 mg/ml oral drops, solution oral use ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
Croatian: - Tropfen 2 mg/ml, 10 mg/ml oralne kapi, otopina kroz usta ratiopharm Arzneimittel Vertriebs-GmbH, Albert-SchweitzerGasse 3, A-1140 Vienna Austria
English: 0.2 g/ 100 ml 1 g/ 100 ml
Croatian: 0.2 g/ 100 ml 1 g/ 100 ml otopina
English: 45, PLACE ABEL GANCE F 92654 BOULOGNE CEDEX
Croatian: Pierre Fabre Médicaments 45, PLACE ABEL GANCE F 92654 BOULOGNE CEDEX
English: 2 mg/ 1 ml 10 mg/ 1 ml
Croatian: 2 mg/ 1 ml 10 mg/ 1 ml otopina
English: Prolonged-released capsule, hard
Croatian: kapsula s prilagođenim oslobađanjem, tvrda
English: 0.20 g /100 ml oral solution
Croatian: 0.20 g /100 ml oralna otopina
English: Dihydroergotaminum Filofarm2 mg/g oral solution
Croatian: Dihydroergotaminum Filofarm2 mg/g oralna otopina
English: DHE "ratiopharm" 5 mg - Kapseln prolonged-release capsule, hard
Croatian: DHE "ratiopharm" 5 mg - Kapseln
English: 0.20 g /100 ml oral drops, solution oral use
Croatian: 0.20 g /100 ml oralne kapi, otopina kroz usta
English: 2 mg/ 1 ml solution
Croatian: 2 mg/ 1 ml otopina
English: Ergovasan 5 mg retard - Kapseln prolonged-release capsule, hard
Croatian: Ergovasan 5 mg retard - Kapseln
English: Ergotam-CT 5,0mg Retardkapseln
Croatian: Ergotam-CT 5,0mg Retardkapseln kapsula s produljenim oslobađanjem
English: Verla-Pharm Arzneimittel GmbH & Co.KG Hauptstr.
Croatian: Verla-Pharm Arzneimittel GmbH & Co.KG Hauptstr. 98 D-82327 Tutzing Germany
English: Ergotam-CT 2,5mg Retardkapseln
Croatian: Ergotam-CT 2,5mg Retardkapseln kapsula s produljenim oslobađanjem
English: Amdipharm Ltd. 3, Burlington Road, Temple Chambers, Dublin 4
Croatian: 3, Burlington Road, Temple Chambers, Dublin 4
English: Ergovasan 2,5 mg retard - Kapseln prolonged-release capsule, hard
Croatian: Ergovasan 2,5 mg retard - Kapseln
English: 2 mg/ml oral solution
Croatian: 2 mg/ml oralna otopina
English: 2 mg/ml oral drops, solution oral use
Croatian: 2 mg/ml oralne kapi, otopina kroz usta
English: Powder for solution for injection/infusion
Croatian: Prašak za otopinu za injekciju/infuziju
English: Pharmaceutical Form
Croatian: Farmaceutski oblik Put primjene
English: Further information on Cimzia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/cimzia.
Croatian: Više informacija o lijeku Cimzia dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/cimzia.
English: The most common side effects with Cimzia (affecting up to 1 in 10 people) are bacterial infections including abscesses (a swollen area where pus has collected), viral infections (including herpes, papillomavirus and influenza), eosinophilic disorders (disorders of eosinophils, a type of white blood cell), leucopenia (low white blood cell counts), nausea (feeling sick), headaches (including migraine), sensory abnormalities (such as numbness, tingling and burning sensation), high blood pressure, hepatitis (liver inflammation) including increased levels of liver enzymes, rash, fever, pain, weakness, itching and reactions at the injection site.
Croatian: Najčešće su nuspojave lijeka Cimzia (koje se mogu javiti u manje od 1 na 10 osoba) bakterijske infekcije uključujući apscese (natečeno područje u kojem se nakupio gnoj), virusne infekcije (uključujući herpes, papilomavirus i influencu), eozinofilni poremećaji (poremećaji eozinofila, tipa bijelih krvnih stanica), leukopenija (mali broj bijelih krvnih stanica), mučnina (slabost), glavobolje (uključujući migrene), osjetilni poremećaji (poput utrnulosti, trnaca i osjećaja peckanja), visok krvni tlak, hepatitis (upala jetre), uključujući povišene koncentracije enzima jetre, osip, vrućica, bol, slabost, svrbež i reakcije na mjestu primjene injekcije.
English: Cimzia is a medicine that is used in adults to treat the following diseases:
Croatian: Cimzia je lijek koji se koristi u odraslih osoba za liječenje sljedećih bolesti:
English: However, the dose of Cimzia used in this study was higher than the usual dose.
Croatian: Međutim, doza lijeka Cimzia primjenjivana u ovom ispitivanju bila je veća od normalne doze.
English: The main measure of effectiveness was the number of patients who responded to treatment after 16 weeks, meaning that symptom scores improved by 75% or more.
Croatian: Glavna mjera učinkovitosti bio je broj bolesnika s odgovorom na terapiju nakon 16 tjedana, što je značilo da su se rezultati simptoma poboljšali za 75 % ili više.
English: Patients will be given a reminder card with safety information that they should carry with them.
Croatian: Bolesnici će dobiti karticu s podsjetnikom s informacijama o sigurnosti lijeka koju trebaju nositi sa sobom.
English: What measures are being taken to ensure the safe and effective use of Cimzia?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Cimzia?
English: These packs will include information on the safety of the medicine.
Croatian: Ti će kompleti sadržavati informacije o sigurnosti lijeka.
English: Cimzia is mostly used for conditions that are severe, moderately severe or getting worse, or when patients cannot use other treatments.
Croatian: Cimzia se prvenstveno koristi za stanja koja su teška, umjereno teška ili se pogoršavaju ili kad bolesnici ne mogu primati druge terapije.
English: Other information about Cimzia
Croatian: Ostale informacije o lijeku Cimzia
English: What is Cimzia and what is it used for?
Croatian: Što je Cimzia i za što se koristi?
English: Similar results were seen in a study with patients who had not adequately responded to other medicines such as methotrexate.
Croatian: Slični rezultati dobiveni su u ispitivanju s bolesnicima u kojih odgovor na druge lijekove, kao što je metotreksat, nije bio odgovarajući.
English: Why is Cimzia authorised in the EU?
Croatian: Zašto je Cimzia odobrena u EU-u?
English: Nine main studies involving over 3,000 patients have found Cimzia effective for reducing symptoms of inflammatory conditions.
Croatian: U devet glavnih ispitivanja u koja je bilo uključeno više od 3 000 bolesnika utvrđeno je da lijek Cimzia učinkovito smanjuje simptome upalnih bolesti.
English: Treatment starts with a 400-mg dose given as two injections, followed by a further 400-mg dose 2 and 4 weeks later.
Croatian: Liječenje započinje dozom od 400 mg koja se daje kao dvije injekcije, nakon čega slijedi dodatna doza od 400 mg dva i četiri tjedna kasnije.
English: Side effects reported with Cimzia are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Cimzia pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Cimzia must not be used in patients with active tuberculosis, other severe infections, or moderate to severe heart failure (inability of the heart to pump enough blood around the body).
Croatian: Lijek Cimzia ne smije se primjenjivati u bolesnika s aktivnom tuberkulozom, drugim teškim infekcijama ili umjerenim ili teškim zatajenjem srca (nemogućnost srca da pumpa dovoljne količine krvi u tijelu).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cimzia have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Cimzia nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: What are the risks associated with Cimzia?
Croatian: Koji su rizici povezani s lijekom Cimzia?
English: After this, depending on the condition being treated, patients should continue with 200 mg or 400 mg, given as one or two injections every 2 or 4 weeks.
Croatian: Poslije toga, ovisno o bolesti koja se liječi, bolesnici trebaju nastaviti s dozom od 200 mg ili 400 mg, davanoj kao jedna ili dvije injekcije svaka dva ili četiri tjedna.
English: By blocking TNF-alpha, certolizumab pegol reduces inflammation and other symptoms of the diseases.
Croatian: Inhibiranjem TNF-alfe, certolizumabpegol smanjuje upalu i druge simptome bolesti.
English: The European Medicines Agency decided that Cimzia's benefits are greater than its risks and that it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Cimzia nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-ui.
English: It is given by injection under the skin, usually in the thigh or abdomen (belly).
Croatian: Primjenjuje se potkožnom injekcijom, najčešće u bedro ili abdomen (trbuh).
English: Cimzia can only be obtained with a prescription and treatment should only be started by a specialist doctor who has experience in diagnosing and treating the diseases that Cimzia is used to treat.
Croatian: Lijek Cimzia izdaje se samo na recept, a liječenje smije započeti samo liječnik specijalist s iskustvom u dijagnosticiranju i liječenju bolesti koje se liječe lijekom Cimzia.
English: Also, X-rays showed that joint damage worsened to a lesser extent in patients who received Cimzia.
Croatian: Rendgenske snimke također su pokazale da se oštećenje zglobova manje pogoršalo u bolesnika koji su primali lijek Cimzia.
English: A monoclonal antibody is a protein that has been designed to recognise and attach to a specific structure in the body.
Croatian: Monoklonsko je protutijelo bjelančevina namijenjena prepoznavanju i vezanju na određene strukture u tijelu.
English: The active substance in Cimzia, certolizumab pegol, reduces the activity of the immune system (the body's defences).
Croatian: Djelatna tvar lijeka Cimzia, certolizumabpegol, smanjuje aktivnost imunosnog sustava (obrambeni sustav tijela).
English: • plaque psoriasis, a disease causing red, scaly patches on the skin.
Croatian: • plak psorijaze, bolesti koja uzrokuje crvene ljuskave lezije na koži.
English: In patients with active rheumatoid arthritis who had never received DMARDs, treatment with Cimzia led to sustained remission (no detectable disease activity) after 52 weeks of treatment.
Croatian: U bolesnika s aktivnim reumatoidnim artritisom koji nikada nisu primali lijekove DMARD, terapija lijekom Cimzia dovela je do održane remisije (bez vidljive aktivnosti bolesti) nakon 52 tjedna liječenja.
English: Pegylation decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
Croatian: Pegiliranje smanjuje brzinu kojom se tvar uklanja iz tijela te stoga omogućuje rjeđu primjenu lijeka.
English: It is made up of a monoclonal antibody, certolizumab, which has been ‘pegylated' (attached to a chemical called polyethylene glycol).
Croatian: Proizvodi se od monoklonskog protutijela, certolizumaba, koji je „pegiliran” (spojen na kemijsku tvar pod nazivom polietilenglikol).
English: The studies included adults with active rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and moderate to severe plaque psoriasis:
Croatian: Ispitivanja su obuhvaćala odrasle osobe s aktivnim reumatoidnim artritisom, aksijalnim spondiloartritisom, psorijatičnim artritisom i umjerenom do teškom plak psorijazom.
English: As for all medicines, data on the use of Cimzia are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Cimzia kontinuirano se prate.
English: An overview of Cimzia and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Cimzia i zašto je odobren u EU-u